Medicine

Molecular profiling of BRAF-V600E-mutant metastatic colon cancer cells in the phase\u00e2 $ 3 LIGHTHOUSE CRC test

.Competing enthusiasms.S.K.: Inventory and Various Other Possession Enthusiasms: Iylon, Lutris, MolecularMatch, Navire. Consulting or even Advisory Part: AbbVie, Amal Therapies, AstraZeneca/MedImmune, Bayer Wellness, Bicara Therapeutics, Boehringer Ingelheim, Boston Ma Biomedical, Carina Biotech, Daiichi Sankyo, EMD Serono, Venture BioMedicines, Blaze Biosciences, Genentech, Gilead Sciences, GSK, HalioDx, Holy Rock Medical Care, Inivata, Ipsen, Iylon, Jacobio, Jazz Drugs, Lilly, Lutris, Merck, Mirati Therapeutics, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx Pharma, Repare Rehab, Servier, Xilis. Analysis Backing: Amgen (Inst), Assortment BioPharma (Inst), Biocartis (Inst), Daiichi Sankyo (Inst), EMD Serono (Inst), Genentech/Roche (Inst), Guardant Health And Wellness (Inst), Lilly (Inst), MedImmune (Inst), Novartis (Inst), Sanofi (Inst). D.A.M.: Employment: Formerly Pfizer. Stock and Various Other Ownership Enthusiasms: Pfizer. J.P.: Job: Formerly Pfizer. Inventory and also Other Ownership Stakes: Pfizer. F.C.: Consulting or even Advisory Function: Amgen, Bayer, Merck KGaA, Pfizer, Roche/Genentech. Study Funding: Amgen (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Ipsen (Inst), Merck KGaA (Inst), MSD (Inst), Roche/Genentech (Inst), Servier (Inst), Symphogen (Inst). J.D.: Consulting or Advisory Function: Amgen (Inst), Bayer, BeiGene, Daiichi Sankyo, Eisai, GSK, Merck KGaA, Pierre Fabre. Investigation Funding: AstraZeneca/MedImmune (Inst), BeiGene (Inst), Bionomics (Inst), Bristol Myers Squibb (Inst), GSK (Inst), Lilly (Inst), Novartis (Inst), Roche (Inst). E.V.C.: Consulting or Advisory Part: AbbVie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, ElmediX, Eisai, GSK, Hookipa Biotech, Incyte, Ipsen, Lilly, Merck Sharp &amp Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seagen, Servier, Simcere, Takeda, Taiho Pharmaceutical, Terumo. H.S.W.: Consulting or Advisory Task: Amgen, Bayer, Bristol Myers Squibb (Celgene), Boehringer Ingelheim (DMC), BTG, EXACT Therapies, Erytech Pharma, Incyte, Merck KGaA, Oaktree Life Sciences, OncoSil, Pfizer, Pierre Fabre, Roche/Genentech, Seagen, Servier, Shire, Sirtex Medical, Takeda (Hutchinson Med), Zymeworks. Investigation Backing: Merck KGaA (Inst), MSD (Inst), Pfizer (Inst), Sirtex Medical (Inst). T.Y.: Honoraria: Bayer Yakuhin, Chugai Pharma, Merck KGaA, MSD, Ono Pharmaceutical, Sumitomo Corp., Takeda. Study Funding: Amgen (Inst), Boehringer Ingelheim (Inst), Chugai Pharma (Inst), Daiichi Sankyo Co., Ltd. (Inst), Eisai, FALCO Biosystems, Genomedia (Inst), Molecular Health And Wellness, MSD (Inst), Nippon Boehringer Ingelheim, Ono Pharmaceutical (Inst), Pfizer (Inst), Roche Diagnostics, Sanofi (Inst), Sumitomo Dainippon (Inst), Sysmex (Inst), Taiho Pharmaceutical (Inst). H.S.: Employment: Pfizer. Supply and Various Other Ownership Claims: Pfizer. X.Z.: Work: Pfizer. Equity as well as Various Other Possession Stakes: Pfizer. Patents, Nobilities, Various Other Intellectual Property: Johns Hopkins College. P.H.: Work: Pfizer. Supply and Various Other Ownership Interests: Pfizer. T.X.: Job: Pfizer. Supply and also Other Possession Interests: Pfizer. R.Y.: Consulting or Advisory Job: Variety BioPharma/Pfizer, Mirati Therapeutics, Zai Laboratory, Amgen. Research Study Funding: Variety BioPharma (Inst), Boehringer Ingelheim (Inst), Mirati Rehab (Inst), Pfizer (Inst), Daiichi Sankyo (Inst). J.T.: Consulting or Advisory Job: Selection BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, HalioDx, Hutchison MediPharma, Ikena Oncology, Inspirna Inc., IQVIA, Lilly, Menarini, Merck Serono, Merus, Mirati Rehabs, MSD, NeoPhore, Novartis, Ona Rehabs, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapy, Seagen Inc., Servier, Taiho Pharmaceutical, Tessa Therapeutics, TheraMyc. Various Other Partnership: Amgen, Range Biopharma, BeiGene, Boehringer Ingelheim, BMS, Cancer Cells Analysis UK, Celgene, Debiopharm, F. Hoffman-La Roche, Fundaciu00c3 u00b3 n Cientu00c3fica de Los Angeles Asociaciu00c3 u00b3 n Espau00c3 u00b1 ola Contra el Cu00c3 u00a1 ncer, Genentech, HalioDX, Hutchinson Medipharma, Imedex, Janssen-Cilag, MedImmune, Medscape, Menarini, Merck Health KGaA, MJH Lifestyle Sciences, MSD, Merus, Mirati, Novartis, Oniria Rehabs, PeerView Institute for Medical Education And Learning, Pfizer, PharmaMar, Physicansu00e2 $ Education And Learning Information, Sanofi-Aventis, Servier, Taiho Drug.